Related Jobs
-
Senior Research Associate
Job Type: Permanent
Salary: RUR 85000.00 per annum
Location: Russia -
CRA
Job Type: Contract
Salary: € 10.00 per hour
Location: Serbia
Company seeks approval for cough drug
11 Jun 2009
Clinical Research
A treatment which aims to tackle the most troublesome coughs has been sent for approval to the US Food and Drug Administration (FDA).
Watson Pharmaceuticals has sent an application to the FDA for the exclusive rights to market the phlegm loosening therapy, guaifenesin pseudoephedrine, otherwise known as Mucinex, which was originally developed by the pharmaceutical company Reckitt Benckiser.
It stated that: "We may be the first applicant to file an application for a generic version of Mucinex and, should its product be approved, we may be entitled to 180 days of generic market exclusivity."
Watson's subsidiary company, Watson Laboratories, tabled the proposal which follows similar applications for cough treatments by the drug giant.
Previous approval attempts have included the application to get permission to market generic versions of the Mucinex drug earlier this year.
That action resulted in a lawsuit being filed against Watson, which is still ongoing.
The news follows Watson's release of Gelnique, the treatment which is aimed at women who suffer from an overactive bladder.
